| |JULY 20238ZAHIL, A SUBSIDIARY OF ZYDUS LIFESCIENCES, ACQUIRES A STAKE IN MYLAB DISCOVERY SOLUTIONSBIOCITY STARTS PHASE 2 TRIAL OF ETA RECEPTOR ANTAGONIST, SC0062 FOR CHRONIC KIDNEY DISEASEZydus Lifesciences, a discovery-driven global life sciences company, has acquired a 6.5 percent stake in Mylab Discovery Solutions from Rising Sun Holdings, an investment company owned by Adar Poonawalla, through its wholly owned subsidiary Zydus Animal Health & Investments Limited (ZAHIL). The acquisition represents a shared vision to transform healthcare by combining the two companies' therapeutic expertise in human formulations and diagnostic capabilities. The transaction is subject to customary closing conditions being met."The research and development capabilities of Zydus in therapeutics, combined with the R&D expertise of Mylab in diagnostics, along with Zydus' last-mile access, have the potential to bring decentralised healthcare solutions to the masses," said Hasmukh Rawal, managing director of Mylab. By focusing on decentralised healthcare, companies can provide timely and accurate diagnostics, effective treatments, and localised healthcare services to individuals, healthcare providers, and communities.""It is the first time in India that a pharmaceutical company, a diagnostic company, and a vaccine manufacturer join forces," said Sujit Jain, director of Strategy at Mylab Discovery Solutions. "I am confident that this collaboration will change the way diseases are diagnosed, treated, and prevented." POBioCityBiopharma, a clinical-stage biopharmaceuti-cal company, announced the start of a randomised, placebo-controlled phase 2 clinical trial of SC0062, a novel oral endothelin A (ETA)-receptor selective antag-onist, in China (NCT05687890). In this multicenter study, SC0062's safety and preliminary efficacy will be com-pared to placebo in patients with chronic renal disease and albuminuria.The initiation of the phase 2 trial follows the successful completion of a phase 1, first-in-human (FIH) trial for SC0062 in healthy volunteers. Clinical data from the FIH study demonstrated a favourable safety profile of SC0062 without reports of the adverse effect of edema in subjects who had received treatment with different doses of SC0062. Currently SC0062 is in phase 2 clinical development for IgAN and DKD (diabetic kidney disease). Data from the ongoing randomized phase 2 trial are expected in 2024.Dr. Yong Jiang Hei, co-CEO of BioCity, stated that ETA receptor antagonists have emerged as a promising therapeutic approach in the field of CKD, and SC0062 is designed with high selectivity for ETA receptors with the objective of ensuring efficacy while avoiding the potential safety risks associated with other molecules in the same class. BiocityBiopharma intends to expedite the ongoing phase 2 clinical trial of SC0062 in order to generate the data necessary to allow informed decision-making on further development of SC0062.Founded in December 2017,BioCity is a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders including chronic kidney diseases (CKD). POTOP STORIES
< Page 7 | Page 9 >